In Vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01595-19. doi: 10.1128/AAC.01595-19. Print 2019 Dec 20.

Abstract

We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the β-lactam-β-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter, including multidrug-resistant and extensively-drug-resistant strains. None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to that of the older agents against Stenotrophomonas maltophilia or Pandoraea spp.

Keywords: ceftazidime-avibactam; ceftolozane-tazobactam; cystic fibrosis; meropenem-vaborbactam; respiratory tract infection.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Achromobacter / drug effects
  • Anti-Bacterial Agents / pharmacology*
  • Boronic Acids / pharmacology
  • Burkholderia / drug effects
  • Cystic Fibrosis / microbiology*
  • Humans
  • Meropenem / pharmacology
  • Microbial Sensitivity Tests
  • Piperacillin / pharmacology
  • Pseudomonas aeruginosa / drug effects
  • Stenotrophomonas / drug effects
  • Stenotrophomonas maltophilia / drug effects
  • Tazobactam / pharmacology
  • beta-Lactamase Inhibitors / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Boronic Acids
  • beta-Lactamase Inhibitors
  • vaborbactam
  • Meropenem
  • Tazobactam
  • Piperacillin